MARKET

CLSD

CLSD

Clearside
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.7506
-0.0657
-8.05%
After Hours: 0.7506 0 0.00% 16:47 09/17 EDT
OPEN
0.8150
PREV CLOSE
0.8163
HIGH
0.8150
LOW
0.7132
VOLUME
659.06K
TURNOVER
--
52 WEEK HIGH
6.75
52 WEEK LOW
0.5600
MARKET CAP
28.34M
P/E (TTM)
-0.3708
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CLSD and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

CLSD News

  • Those Who Purchased Clearside Biomedical (NASDAQ:CLSD) Shares Three Years Ago Have A 93% Loss To Show For It
  • Simply Wall St..20h ago
  • 25 Healthcare Stocks Moving In Wednesday's Pre-Market Session
  • Benzinga.6d ago
  • Edited Transcript of CLSD earnings conference call or presentation 7-Aug-19 8:30pm GMT
  • Thomson Reuters StreetEvents.09/09 21:14
  • This Rockville biotech has added another deal to its growth plan
  • American City Business Journals.09/09 17:58

More

Industry

Biotechnology & Medical Research
+0.24%
Pharmaceuticals & Medical Research
+0.57%

Hot Stocks

Name
Price
%Change

About CLSD

Clearside Biomedical, Inc. is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company's product candidates focus on diseases affecting three components of the eye: the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision; the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment, and the sclera, which is the outer protective layer of the eye. The Company’s lead product candidate, XIPERE, is a proprietary, preservative-free suspension of the corticosteroid triamcinolone acetonide formulated for administration via suprachoroidal injection.
More

Webull offers Clearside Biomedical Inc (CLSD) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.